These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

466 related items for PubMed ID: 25352393

  • 21. Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor.
    Yamamoto K, Tanabe N, Suda R, Sasaki A, Matsumura A, Ema R, Kasai H, Kato F, Sekine A, Nishimura R, Jujo T, Sugiura T, Shigeta A, Sakao S, Tatsumi K.
    Respir Investig; 2017 Jul; 55(4):270-275. PubMed ID: 28705306
    [Abstract] [Full Text] [Related]

  • 22. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2).
    Simonneau G, D'Armini AM, Ghofrani HA, Grimminger F, Hoeper MM, Jansa P, Kim NH, Wang C, Wilkins MR, Fritsch A, Davie N, Colorado P, Mayer E.
    Eur Respir J; 2015 May; 45(5):1293-302. PubMed ID: 25395036
    [Abstract] [Full Text] [Related]

  • 23. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study.
    Halank M, Hoeper MM, Ghofrani HA, Meyer FJ, Stähler G, Behr J, Ewert R, Fletcher M, Colorado P, Nikkho S, Grimminger F.
    Respir Med; 2017 Jul; 128():50-56. PubMed ID: 28610669
    [Abstract] [Full Text] [Related]

  • 24. Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH.
    Gall H, Vachiéry JL, Tanabe N, Halank M, Orozco-Levi M, Mielniczuk L, Chang M, Vogtländer K, Grünig E.
    Lung; 2018 Jun; 196(3):305-312. PubMed ID: 29470642
    [Abstract] [Full Text] [Related]

  • 25. Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Marra AM, Egenlauf B, Ehlken N, Fischer C, Eichstaedt C, Nagel C, Bossone E, Cittadini A, Halank M, Gall H, Olsson KM, Lange TJ, Grünig E.
    Int J Cardiol; 2015 Sep 15; 195():19-26. PubMed ID: 26011408
    [Abstract] [Full Text] [Related]

  • 26. [Riociguat: stimulator of soluble guanylate-cyclase. New mode of action for the treatment of pulmonary arterial and non operable chronic thromboembolic pulmonary hypertension].
    Leuchte HH, Behr J, Ewert R, Ghofrani HA, Grünig E, Halank M, Held M, Klose H, Rosenkranz S, Schermuly RT, Wilkens H, Hoeper MM.
    Pneumologie; 2015 Mar 15; 69(3):135-43. PubMed ID: 25750094
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Riociguat: first global approval.
    Conole D, Scott LJ.
    Drugs; 2013 Nov 15; 73(17):1967-75. PubMed ID: 24218053
    [Abstract] [Full Text] [Related]

  • 29. Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Hill NS, Rahaghi FF, Sood N, Frey R, Ghofrani HA.
    Respir Med; 2017 Aug 15; 129():124-129. PubMed ID: 28732819
    [Abstract] [Full Text] [Related]

  • 30. Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Benza RL, Langleben D, Hemnes AR, Vonk Noordegraaf A, Rosenkranz S, Thenappan T, Hassoun PM, Preston IR, Ghio S, Badagliacca R, Vizza CD, Lang IM, Meier C, Grünig E.
    Eur Respir Rev; 2022 Dec 31; 31(166):. PubMed ID: 36198418
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration.
    Hill NS, Badesch D, Benza RL, D'Eletto TA, Farber HW, Gomberg-Maitland M, Hassoun PM, Preston I.
    Ann Am Thorac Soc; 2015 Feb 31; 12(2):269-73. PubMed ID: 25590376
    [Abstract] [Full Text] [Related]

  • 33. Riociguat as a treatment regime for pulmonary arterial hypertension: a review.
    Narang BK, Roy S, Sharma R, Singh V, Rawal RK.
    Clin Exp Hypertens; 2015 Feb 31; 37(4):323-31. PubMed ID: 25268409
    [Abstract] [Full Text] [Related]

  • 34. Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial.
    Simonneau G, D'Armini AM, Ghofrani HA, Grimminger F, Jansa P, Kim NH, Mayer E, Pulido T, Wang C, Colorado P, Fritsch A, Meier C, Nikkho S, Hoeper MM.
    Lancet Respir Med; 2016 May 31; 4(5):372-80. PubMed ID: 27067478
    [Abstract] [Full Text] [Related]

  • 35. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.
    Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, Mayer E, Simonneau G, Wilkins MR, Fritsch A, Neuser D, Weimann G, Wang C, CHEST-1 Study Group.
    N Engl J Med; 2013 Jul 25; 369(4):319-29. PubMed ID: 23883377
    [Abstract] [Full Text] [Related]

  • 36. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension.
    Ikeda N.
    Cardiovasc Interv Ther; 2020 Apr 25; 35(2):130-141. PubMed ID: 31873853
    [Abstract] [Full Text] [Related]

  • 37.
    ; 2015 07 25. PubMed ID: 26962600
    [Abstract] [Full Text] [Related]

  • 38. Balloon pulmonary angioplasty versus riociguat in inoperable chronic thromboembolic pulmonary hypertension (MR BPA): an open-label, randomised controlled trial.
    Kawakami T, Matsubara H, Shinke T, Abe K, Kohsaka S, Hosokawa K, Taniguchi Y, Shimokawahara H, Yamada Y, Kataoka M, Ogawa A, Murata M, Jinzaki M, Hirata K, Tsutsui H, Sato Y, Fukuda K.
    Lancet Respir Med; 2022 Oct 25; 10(10):949-960. PubMed ID: 35926544
    [Abstract] [Full Text] [Related]

  • 39. Soluble guanylate cyclase stimulators in pulmonary hypertension.
    Stasch JP, Evgenov OV.
    Handb Exp Pharmacol; 2013 Oct 25; 218():279-313. PubMed ID: 24092345
    [Abstract] [Full Text] [Related]

  • 40. Modern view on the place of riociguat in the treatment of pulmonary hypertension.
    Valieva ZS, Taran IN, Martynyuk TV, Chazova IY.
    Ter Arkh; 2018 Apr 19; 90(4):55-59. PubMed ID: 30701875
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.